Publicaciones Relacionadas:
-Gangoso E, Thirant C, Chneiweiss H, Medina JM, Tabernero A. A cellpenetrating peptide based on the interaction between c-Src andconnexin43 reverses glioma stem cell phenotype. Cell Death Dis. 2014; 5(1):e1023.
-Jaraíz-Rodríguez M, Tabernero MD, González-Tablas M, et al. A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK. Stem Cell Reports. 2017; 9(2):451-463.
-Pelaz SG, Jaraíz-Rodríguez M, Álvarez-Vázquez A, et al. Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TATCx43. EBioMedicine. 2020; 62:103134.
-Pelaz SG, Ollauri-Ibáñez C, Lillo C, Tabernero A. Impairment of Autophagic Flux Participates in the Antitumor Effects of TAT-Cx43. Cancers (Basel). 2021; 13(17).
-García-Vicente L. The anti-tumor peptide Tat-Cx43266-283 Modulates the interplay between glioblastoma cells and tumorassociatedastrocytes, University of Salamanca; 2022.
-Jaraíz-Rodríguez M, Talaverón R, García-Vicente L, et al. Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, andenhances survival in mouse models in vivo. Neuro Oncol. 2020; 22(4):493-504.
-Álvarez-Vázquez A, San-Segundo L, Cerveró-García P, et al. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models. Neuro Oncol. 2024. 20:noae060.